InvestorsObserver
Sign Up Login

BGLC Bionexus Gene Lab Corp

$0.57 $0.00 (0.68%)
15 Minute Delayed Price Enable Real-Time Price
Add to Watchlist Compare
Overall

BGLC Stock Analysis Overview

What this means: InvestorsObserver gives Bionexus Gene Lab Corp (BGLC) an overall rank of 27, which is below average. Bionexus Gene Lab Corp is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. A rank of 27 means that 73% of stocks appear more favorable to our system.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

View Sample Report
Fundamental PREMIUM

BGLC Fundamental Analysis

Who this matters to: The Fundamental Ranking considers the health of the underlying company. It is best used by longer-term buy-and-hold investors.

Upgrade to Premium to unlock Fundamental Ranking

Short-Term Technical PREMIUM

BGLC Short-Term Technical Analysis

Who this matters to: The Short-Term Technical Ranking evaluates a stock’s trading over the past month. This is most useful for short- to medium-term stock and option traders.

Upgrade to Premium to unlock Short-Term Technical Ranking

Long-Term Technical PREMIUM

BGLC Long-Term Technical Analysis

Who this matters to: The Long-Term Technical Ranking is a good gauge of how a stock has traded over the past several months. This is useful for medium to long-term stock and option traders.

Upgrade to Premium to unlock Long-Term Technical Ranking

Analyst Ranking PREMIUM

BGLC Analyst Ranking

Who this matters to: Analyst Ranking shows you which stocks Wall Street analysts like the most. Since analysts build valuation models, this is most useful for medium to long-term investors who are interested in a valuation-based approach.

Upgrade to Premium to unlock Analyst Ranking Analysis

Valuation PREMIUM

BGLC Valuation Ranking Analysis

Who this matters to: Valuation Ranking is most-useful for value-focused investors who plan to hold a stock for the long term.

Upgrade to Premium to unlock Valuation Ranking

Stock Sentiment PREMIUM

BGLC Stock Sentiment Analysis

Who this matters to: Sentiment Rank looks at the past five trading days. This is our shortest-term evaluation and is best used by people with a very short horizon.

Upgrade to Premium to unlock Stock Sentiment Ranking

BGLC Stock Analysis Overview

What this means: InvestorsObserver gives Bionexus Gene Lab Corp (BGLC) an overall rank of 27, which is below average. Bionexus Gene Lab Corp is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. A rank of 27 means that 73% of stocks appear more favorable to our system.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

Create a FREE account to see full BGLC report

BGLC Fundamental Analysis

Who this matters to: The Fundamental Ranking considers the health of the underlying company. It is best used by longer-term buy-and-hold investors.

Upgrade to Premium to unlock Fundamental Ranking

BGLC Short-Term Technical Analysis

Who this matters to: The Short-Term Technical Ranking evaluates a stock’s trading over the past month. This is most useful for short- to medium-term stock and option traders.

Upgrade to Premium to unlock Short-Term Technical Ranking

BGLC Long-Term Technical Analysis

Who this matters to: The Long-Term Technical Ranking is a good gauge of how a stock has traded over the past several months. This is useful for medium to long-term stock and option traders.

Upgrade to Premium to unlock Long-Term Technical Ranking

BGLC Analyst Ranking

Who this matters to: Analyst Ranking shows you which stocks Wall Street analysts like the most. Since analysts build valuation models, this is most useful for medium to long-term investors who are interested in a valuation-based approach.

Upgrade to Premium to unlock Analyst Ranking Analysis

BGLC Valuation Ranking Analysis

Who this matters to: Valuation Ranking is most-useful for value-focused investors who plan to hold a stock for the long term.

Upgrade to Premium to unlock Valuation Ranking

BGLC Stock Sentiment Analysis

Who this matters to: Sentiment Rank looks at the past five trading days. This is our shortest-term evaluation and is best used by people with a very short horizon.

Upgrade to Premium to unlock Stock Sentiment Ranking

Bionexus Gene Lab Corp (BGLC) Analyst Forecast

BGLC Price, Volume, Earnings, and Dividend Date

  • Last Price $0.57
  • Previous Close $0.57
  • Change $0.00
  • Open $0.56
  • Volume 37,748
  • Avg. Volume (100-day) 1,002,769
  • Market Cap 10,139,472
  • Days Range 0.56 - 0.5897
  • 52-week Range 0.31 - 17.88
  • Dividend Yield —
  • Ex. Dividend Date —
  • P-E —
  • EPS —
  • Earnings Date —
  • Sector —
  • Industry —
  • Avg. Analyst Rec. Premium
  • Beta -1.115
  • PEG Ratio —

Bionexus Gene Lab Corp (BGLC) Company Description

BioNexus Gene Lab Corp is an emerging molecular diagnostics company focused on the application of functional genomics to enable early diagnosis and personalized health management. It focuses on developing and marketing safe, effective, and non-invasive blood tests for the early detection of diseases. The company's non-invasive blood tests analyze changes in ribonucleic acid (or RNA) to detect the potentiality of 11 different diseases. These diseases include eight cancers (nasopharyngeal, lung, liver, stomach, breast, cervical, prostate, and colon), two bowel diseases (colitis and Crohn), and osteoarthritis.

Bionexus Gene Lab Corp (BGLC) Stock Chart

View Interactive BGLC chart

My Watchlists

Top Stocks